Topical Hemostatic Agents Patents: Top Companies & Trends 2026
Topical Hemostatic Agents Patents: Who Leads and Where Filing Is Heading
41.1% concentration. The top 5 assignees hold 2,680 of 6,517 records in scope — a field where a handful of surgical and biopharma names have staked most of the claim space. Publications rose to 293 in 2017, the peak so far, then declined through the last complete year on record. The -52% move from 220 records in 2021 to 105 in 2024 is the clearest complete-year signal available; years after 2024 are still filling in as publications catch up to filing dates roughly 18 months behind.
- 1ETHICON INC13.2%
- 2BIOVERATIV THERAPEUTICS INC9.5%
- 3ETHICON ENDO SURGERY INC7.2%
- 4CILAG GMBH INTERNATIONAL7.2%
- 5BAXTER INT INC4.1%
See the full topical hemostatic agents analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about topical hemostatic agent patents
Who holds the most patents on topical hemostatic agents?
The dataset’s assignee ranking shows one company holding 858 records, well ahead of the next-ranked filers. The top 5 assignees combined account for 2,680 records, or 41.1% of the 6,517 records in scope, and the top 10 extend that to 52.3%. That leaves roughly half the field’s output distributed across a long tail of smaller filers, so a newcomer’s competitive check should look well beyond the top names.
Is patent filing in topical hemostatic agents growing or shrinking?
Filings peaked at 293 records in 2017 and have declined since, with the clearest complete-year signal being a -52% drop from 220 records in 2021 to 105 in 2024. Years after 2024 show lower counts still, but publication typically lags filing by around 18 months, so the most recent one to two years understate true activity rather than proving a further decline. Treat 2024 as the last reliable data point for trend reading.
Which patent classes cover topical hemostatic agent chemistry versus devices?
A61K (medicinal preparations) and A61L (sterilising and disinfecting) each cover roughly 40% of the 6,517 records and represent the formulation and material-sterility core of the field. A61B (diagnosis and surgery, 25.1%) and A61F (implants and prostheses, 13.6%) capture the device-integration side, while C08L (polymer compositions, 4.8%) is comparatively thin. Because records can carry multiple IPC codes, these shares add up to more than 100% of the record total.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Topical Hemostatic Agents covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.